<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05002764</url>
  </required_header>
  <id_info>
    <org_study_id>CHUBX 2021/33</org_study_id>
    <nct_id>NCT05002764</nct_id>
  </id_info>
  <brief_title>Thalamic Nuclei Volumes in Multiple Sclerosis</brief_title>
  <acronym>THALNUC-MS</acronym>
  <official_title>Differential Vulnerability of Individual Thalamic Nuclei: Toward New Biomarkers in Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bordeaux</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Bordeaux</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The thalamus is composed of several nuclei interlocked in a complex anatomy. In multiple&#xD;
      sclerosis (MS), the thalamus can be altered due to disconnection by white matter lesions and&#xD;
      due to direct damages that could be partly mediated by CSF. Due to such pathophysiology and&#xD;
      complex anatomy, some nuclei could be more vulnerable to multiple sclerosis than others. We&#xD;
      will test this hypothesis by using a new algorithm to automatically segment several nuclei&#xD;
      that we will be applied to the French national MS database&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2021</start_date>
  <completion_date type="Anticipated">July 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2023</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <target_duration>24 Years</target_duration>
  <primary_outcome>
    <measure>Volume of thalamic nuclei</measure>
    <time_frame>At inclusion in the cohort</time_frame>
    <description>Volume of individual thalamic nuclei according to disease duration.</description>
  </primary_outcome>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Multiple Sclerosis</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with Multiple Sclerosis and at least one MRI that includes 3D T1 and FLAIR at 1.5T&#xD;
        or 3T.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria :&#xD;
&#xD;
          -  Patient older than 18 years old.&#xD;
&#xD;
          -  With Multiple Sclerosis according to Mc Donald 2017 criteria or with clinically&#xD;
             isolated syndrome and included with OFSEP cohort.&#xD;
&#xD;
          -  Phenotype known (RR, SP, PP or CIS).&#xD;
&#xD;
          -  Date of diagnosis known.&#xD;
&#xD;
          -  With at least one MRI that includes 3D T1 and FLAIR at 1.5T or 3T.&#xD;
&#xD;
        Exclusion Criteria :&#xD;
&#xD;
          -  Stroke&#xD;
&#xD;
          -  Other causes of dementia not caused by Multiple Sclerosis (Alzheimer's disease,&#xD;
             Parkinsonian syndromes…)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Thomas Tourdias, Pr</last_name>
    <phone>05 56 79 56 04</phone>
    <email>thomas.tourdias@chu-bordeaux.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <zip>33 076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas TOURDIAS, Pr</last_name>
      <phone>05 56 79 56 04</phone>
      <email>thomas.tourdias@chu-bordeaux.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 4, 2021</study_first_submitted>
  <study_first_submitted_qc>August 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 12, 2021</study_first_posted>
  <last_update_submitted>August 4, 2021</last_update_submitted>
  <last_update_submitted_qc>August 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple sclerosis</keyword>
  <keyword>Thalamus</keyword>
  <keyword>Nuclei</keyword>
  <keyword>Atrophy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

